Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
IMMUNOGLOBULIN G
Octapharma Limited
IMMUNOGLOBULIN G
165 Mg/Ml
Solution for Injection
Product subject to prescription which may not be renewed (A)
Withdrawn
2009-06-11
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0521/014/001 Case No: 2050397 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to OCTAPHARMA LIMITED THE ZENITH BUILDING, 26 SPRING GARDENS, MANCHESTER, M2 1AB, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product GAMMANORM, 165 MG/ML SOLUTION FOR INJECTION. HUMAN NORMAL IMMUNOGLOBULIN, AMPOULE. The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 15/10/2008. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 27/02/2009_ _CRN 2050397_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT GAMMANORM, 165 mg/ml, solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg) Human normal immunoglobulin 165 mg/ml* *corresponding to human protein content of which at least 95 % is IgG. One ampoule of 10 ml contains: 1650 mg * of human normal immunoglobulin. Distribution of IgG subclasses: IgG 1 59% IgG 2 36% IgG 3 4.9% IgG 4 0.5% IgA max. 82.5 microgram/ml For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear or slightly opalescent and pale yellow to light-brown Przeczytaj cały dokument